Delta-tocopherol Modulation of Cholesterol Recycling in Lysosomal Storage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lysosomal storage disorders, particularly Niemann-Pick type C disease, lack an effective cure and are hindered by high drug development failure rates due to unpredictable toxicity and disproportionate efficacy between human and model systems, with existing therapies only providing symptom relief.
Innovation Solution
The use of delta-tocopherol, either alone or in combination with cyclodextrin, to reduce cholesterol accumulation and lysosome size in cells, facilitating an alternative cholesterol recycling pathway to address the underlying trafficking defects in lysosomal storage disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If alpha-tocopherol is used as the primary treatment, then antioxidant effects are provided, but potency in reducing cholesterol accumulation is insufficient compared to delta-tocopherol
Solution Approach 1:
The patent changes the chemical parameter from alpha-tocopherol to delta-tocopherol, which has different molecular structure properties (four methyl groups vs. one methyl group). This parameter change results in significantly enhanced potency for reducing cholesterol accumulation in lysosomal storage disorders, directly resolving the contradiction between therapeutic efficacy and cholesterol reduction capability.
2Reliability
If high dosages of tocopherol are used to achieve therapeutic effect, then cholesterol accumulation is reduced, but cytotoxicity increases
Solution Approach 1:
The patent changes the tocopherol isomer from alpha to delta, which alters the dose-response relationship. Delta-tocopherol achieves therapeutic effects at lower concentrations with a wider safety margin, reducing cytotoxicity while maintaining efficacy. This parameter change resolves the contradiction between therapeutic effect and harmful side effects.
3Object-affected harmful factors
If existing therapies are used for symptom relief, then patient comfort is improved, but underlying trafficking defects are not addressed
Solution Approach 1:
The patent extracts and targets the root cause mechanism by using delta-tocopherol to specifically address cholesterol trafficking defects in the lysosomal pathway. Rather than merely relieving symptoms, the treatment extracts and corrects the underlying transport defect, resolving the contradiction between symptom management and disease progression.
4Reliability
If combination therapy with cyclodextrin is used, then synergistic therapeutic effect is achieved, but treatment complexity increases
Solution Approach 1:
The patent combines delta-tocopherol with cyclodextrin in a unified treatment regimen. The cyclodextrin component enhances the solubility and delivery of delta-tocopherol, creating a synergistic effect that improves therapeutic efficacy while the combination is administered through a single integrated protocol, managing the complexity of the treatment.
Data Source
AI summary
This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of δ tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders. Included in the present disclosure is a method for the modulation of cholesterol recycling. Further, the disclosure relates to conditions such as Niemann-Pick type C disease, Farber disease, Niemann-Pick type A disease, Wolman disease and Tay Sachs disease. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of δ tocopherol. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of δ tocopherol in combination with cyclodextrin to a patient in need thereof.